Wednesday 30 November 2016

Technology of Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

Researchmoz added Most up-to-date research on "Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description" to its huge collection of research reports.

GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

Scope

    An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment
    Analysis of the major systemic therapies in the current psoriasis marketed landscape
    Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
    Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
    Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=186872

Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 5

2 Executive Summary 6
2.1 Changes to Treatment Usage Patterns will Drive Market Growth 6
2.2 Biologics to Gain Prominence as Promising Novel Drugs Enter the Market 6

3 Introduction 7
3.1 Overview 7
3.2 Epidemiology 8
3.3 Etiology, Co-morbidities and Risk Factors 9
3.3.1 Genetics 9
3.3.2 Psoriatic Arthritis 9
3.3.3 Mental Health Disorders 10
3.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 10
3.3.5 Infections 10
3.3.6 Köebner Phenomenon 11

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

No comments:

Post a Comment